Support heart and blood flow

The hour-by-hour rise comes from single doses given in short test sessions, which may not match a regular drinker's morning cup. Only three trials, of about 2 weeks each, looked past the first day, too short to catch a change that builds more slowly. An older review found the rise strongest in people who already have high blood pressure, so it may be smaller in others.

Coffee habits were self-reported and chosen, not assigned. People worried about their blood pressure may cut back, which would hide a rise among heavier drinkers. An earlier pooling of six studies found 9% higher risk at 1 to 3 cups a day and no rise above 3. American studies found slightly lower risk and European ones did not, so the overall figure averages a real split.

The trials gave caffeine itself, not coffee, at doses and for lengths that varied from trial to trial. Eight trials is a small base to split by sex, dose and length, so those three patterns are leads rather than settled findings. The clearest dose effect, above 400 mg a day, was in diastolic pressure.

One trial of 48 people, and it was designed to study caffeine, with theanine as the modifier rather than the subject. For anyone taking theanine by itself for calm focus, the same trial is a null result: alertness, jitteriness and mood did not move.

The short trials and the long follow-ups measure different things, weight on one side and disease on the other, so neither one checks the other. The long-term half only watched what people already drank, and people already at higher risk switching to diet drinks would produce the same pattern. This is a joint position from the Korean Diabetes Association and Korean Nutrition Society rather than a new analysis.

This only tracks a pattern over time, so it cannot show cause. Just 32 of the deaths were from heart disease, which makes the estimate rough. Cortisol was measured on one ordinary weekday. Morning cortisol on its own showed no link at all.

The community data are observational, so doctors steering higher-risk patients towards particular drugs cannot be ruled out. A relative risk says nothing about a given reader's own starting point. In the randomised trials the absolute excess came to about three extra major vascular events per 1,000 people treated for a year, one of them fatal. Those trial doses were high and sustained.

The larger figures come from a slice of the data examined after the fact rather than the review's main comparison, which makes them the weaker number even though they are the more striking one. The ten pooled reviews overlap, so some of the same original trials are counted more than once. And blood pressure is a stand-in here: none of these trials counted heart attacks or strokes.

The trial registry lists two melatonin trials in heart failure, one withdrawn and one with no update since 2020. Of the registered melatonin insomnia trials screened, only 13% had posted results, so some safety data may never have been published.

The study measured an inherited tendency to insomnia and never looked at melatonin or any sleep aid. Everyone in it was of European ancestry. About 28% of the people in the insomnia gene data were also in the heart data, which can pull the estimate toward an ordinary association, though the authors judged that bias likely small.

The review mixed trials in children and adults, so the rates are not adults' alone. Only 8 of the 37 trials were rated good quality, and 13 were rated poor. No rate was given for palpitations.

These were high, sustained, prescription-level doses in people with arthritis, not occasional tablets. Every regimen studied raised upper-gut complications, so this is a ranking inside a class that all carried the risk, not a safe option beside a risky one. Heart failure risk was roughly doubled by every drug in the analysis, naproxen included.

The over-60 systolic figure is a subgroup finding inside a 349-person pool, which generates a hypothesis rather than confirming one. The analysis assumed one true effect across trials spanning 250 to 2,000 mg a day and 14 days to 24 weeks, which narrows the confidence interval by assumption rather than by evidence. No trial in the pool measured a heart attack or a stroke; the reading on the cuff is the entire result.

For the other oral decongestants pooled in that search, a week or more of daily use changed systolic pressure by 0.91 mmHg on average, at very low certainty. None of those trials used phenylephrine, so the figure cannot be carried over to it.

The trial cannot separate how much of the benefit came from the weight loss and how much from the drug's other effects, since the treated arm got both. Adverse events forced 16.6% off the drug permanently, against 8.2% on placebo, in a group with strong reason to persist. Novo Nordisk funded it and employed several of the authors.

Six minutes of walking stands in for exercise capacity, not for living longer: the trial ran twelve weeks, was not powered for mortality, and found no significant difference in clinical worsening. It also enrolled only certain causes of raised lung pressure.

The largest of those changes is 7 mg/dL, under 5 percent of a typical level. Reductions were bigger in people who started with high cholesterol, so anyone starting from normal should expect less. Only 11 trials, none of them published after 2006.

The trial was powered for artery thickening rather than for sexual outcomes, so the null on sex is a secondary result rather than a definitive one. Its authors say plainly that it should not be read as establishing cardiovascular safety. Haematocrit and prostate-specific antigen both rose more on testosterone.

Participants were picked for being unusually healthy for their age, with no major health event in five years and good mobility, so a frailer group might respond differently. Testing six outcomes at once, the authors demanded a p value below 0.01, a strict bar that would hide a modest real effect. Three years is short for both fractures and cognition.

Neither trial screened people in for low vitamin D, so both test adding more to people who mostly had enough rather than correcting a shortfall. The Australian participants averaged 77 nanomoles per litre before they started, in a country with a great deal of sun. Five years may be short for cancers that take longer than that to surface.

Something else in cola, or about the people who drink it, may carry the risk, and the authors could not say what. Caffeine intake was not flat either: women in the middle fifth had 12 to 13% higher risk than the lowest. Both intake and diagnosis were reported by the women themselves.

One hospital, 250 people. Facing major surgery can itself distort cortisol patterns, so this may not reflect ordinary life. A flatter drop may also mark someone who is already sicker, rather than adding risk of its own.

Nobody swallowed anything: these were extracts applied to platelets in a tube, at concentrations matching no serving or capsule. The same paper's introduction cites an earlier report that a lion's mane extract did interfere with one platelet receptor, so even the tube evidence is split.

Everyone in these trials already had one of those conditions, so a healthy adult has no reason to expect the same shift. The trials ran between one and six months, which says nothing about a year on it. And 543 people across 11 trials is a modest base for a figure this precise.

The three trials enrolled 201 people in all. The estimate ran from about a 2-point fall to a 6-point rise in ejection fraction, so a small effect either way is not ruled out. Harms were reported inconsistently across the trials. A second review reaching the same result drew on some of the same trials.

Thirty-six people is small for a vascular endpoint, so this cannot rule out a modest real effect. The paper's own closing line says NMN showed potential in alleviating arterial stiffness, which is a firmer reading than its numbers support. The work was done in the laboratories of a Japanese supplement company, though the authors declare no competing interests.

These are relative risks, and the review does not supply an absolute one, which turns heavily on age and ulcer history. What counted as a serious complication varied between the pooled studies. The high-dose randomised data come from prescription-level regimens given to people with arthritis, not from the occasional tablet. Risk did not appear to keep climbing past the first month.

These are reports of individual cases gathered in a narrative review, so they show that it can happen, not how often.

Both studies gave single doses, so neither shows what a day or a week of doses does. Everyone in them had normal blood pressure. The larger study was run by employees of a phenylephrine maker. A model built from eye-drop data predicts a larger rise when 10 mg is taken with 1,000 mg of acetaminophen, 12.3 against 4.2 mmHg in average arterial pressure, a prediction nobody has measured.

The rule is written from blood-pressure measurements, not from counted faints or falls. How much it matters may depend on how long a man has already been on his alpha-blocker, and the review reporting that describes it as suggested rather than settled.

Thirty-one men in total across two crossover trials, all with stable angina, so the exact size of the fall need not transfer to anyone else. Blood pressure was what these trials counted, not faints, heart attacks or deaths, and a trial counting those in people on nitrates will never be run.

A prescribing label sets doses and rules without publishing the data behind them, and its wording is negotiated between a manufacturer and a regulator. Both of these are the US labels, and neither describes what doctors do outside them.

Nobody was assigned to drink coffee, so whatever else separates a three-cup habit from none, in diet, smoking, exercise or income, is folded into that number. Coffee carries hundreds of compounds besides caffeine, and nothing here tells them apart. The size of the association differed by region, running stronger in Europe and Asia than in the US.

That coffee drinkers die less often is not in doubt; whether anything in the cup causes it is. Nobody was assigned to drink coffee, and nothing separates caffeine from the hundreds of other compounds in it.

Both pools followed what people already chose to drink, so these are links rather than proof that either drink causes anything. Someone told to watch their weight or blood sugar tends to switch to diet, which would draw this same pattern with no effect from the drink at all. The pooled studies varied widely in their results for several of these outcomes. And these are drink categories, not Coca-Cola and Coca-Cola Zero specifically.

The cohorts were stable cardiac patients, not supplement users, so the absolute risk does not transfer to anyone taking a capsule. The human half is observational, though 4PY at physiological levels switched on the vascular inflammation machinery in mice and a genetic analysis across 106,000 people pointed the same way. Every trial of these supplements that measured the metabolites ran weeks to months, far too short for a heart attack to be an endpoint.

Nearly seven in ten participants stopped taking the study drug and more than a quarter stopped follow-up altogether, which blunts every comparison the trial makes. It was funded by celecoxib's manufacturer. A non-inferiority design can show one drug is not clearly worse than another; it cannot show that any of them is safe. Everyone enrolled had arthritis and raised cardiovascular risk.

Whether celecoxib is as heart-safe as ibuprofen and naproxen is unsettled. Prescribing data rank it riskier; the one large trial found it no worse but dosed the drugs unequally, and no study has compared them at matched doses.

Noninferiority means testosterone was not worse than placebo by more than a preset margin, which is a different statement from safe. The three excess events were not adjusted for multiple comparisons and the trial was not powered to find them. Doses were titrated into the low-to-mid normal range, so nothing here speaks to higher amounts. The trial was funded by testosterone manufacturers.

Whether testosterone harms the arteries is unresolved. The largest trial found no rise in major cardiac events; an imaging trial found more non-calcified plaque after a year. Nobody has shown whether that plaque turns into events.

Each man was his own comparison, which handles his fixed characteristics but not a new illness or hospital stay that could prompt both a prescription and a clot. Only 7.8% of the men had a hypogonadism diagnosis code at all. A prescription record shows the drug was dispensed, not that it was taken.

Whether testosterone raises clot risk is unsettled. Insurance claims show about double the odds and the randomised trial no overall excess, yet both point the same way on clots in the lung, the part of the signal that has not gone away.

No point estimates or confidence intervals appear for either direction, so the size of this is unknown. Genetic proxies for circulating amounts are not a test of taking a supplement. Exposure and outcome samples overlap, which can pull the estimate towards the plain observed association.

Tested in one direction, high blood branched-chain amino acids look like a result of poor metabolic health; tested in reverse, like a cause of worse blood fats. No effect size was given for either, so how much each matters is open.

Eleven people give only a rough picture of when the rise fades and how completely. One moderate dose was tested, about 210 mg for a 70 kg adult, not the range people drink.

In one small trial, daily caffeine's blood-pressure rise faded to near zero within three weeks; pooled trials found about 2 mmHg that was larger in longer trials. Whether the body adapts fully or only partly is unsettled.

People who choose supplements differ from people who do not in ways no adjustment removes, and a modest reduction turning up in every outcome at once is what that difference usually produces. Preparation and amount went unrecorded. No randomised trial has tested glucosamine against heart outcomes.

Both figures are relative, and neither set of authors supplies the baseline that would turn them into a personal number. The randomised trials used high, sustained, prescription-level doses in people with arthritis. The database analysis infers what people took from prescription records, so anything bought over the counter is invisible to it. A third pooled review of community databases put naproxen lowest of all, at 1.09.

Whether naproxen is the heart-safe painkiller is unsettled. Trials and prescribing databases disagree, and the databases disagree with each other, along study design rather than dose.

Twenty-four people in a crossover design, six weeks per arm, all of them healthy, so this is an early tolerability and target-engagement study rather than a test of anything. NAD was measured in blood, which shows the pill is absorbed and metabolised, not that it reached the tissues where ageing is supposed to slow. The trial was investigator-initiated at a university with no declared competing interests, which sets it apart from most of this literature.

This was an extension study, not the randomised trial: children carried their original dose assignment forward while former placebo recipients were newly randomised, so the groups did not start alike. Those who died were far likelier to have the severe inherited forms and worse baseline function.

In a long-term follow-up, children on the highest sildenafil dose died at nearly four times the lowest-dose rate. Whether dose caused it is open: the groups did not start alike, and the sickest children were over-represented among deaths.

Both papers were written to explain a single conference report that had not been peer-reviewed. The letter proposing the blood-pressure route also says untreated insomnia could explain the same result.

With no comparison group and no count of people who took melatonin without trouble, the cases cannot give a rate. The link rests on timing and on recovery after stopping, with no formal causality score applied. Heart block is a rhythm problem, not heart failure.